Helix BioPharma Corp. sees a modest weekly uptick amid recent financial disclosures.
Helix BioPharma Corp. (HBP.TO) has experienced a 4.17% increase over the past week, closing at C$1.50. This performance comes alongside a series of financial updates and strategic moves by the company, which are worth examining for investors considering their position in the health care sector.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$114.57M
52W high
$5.40
52W low
$0.98
1W change
+4.17%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 66.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+66.7% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
50.6%
Annualized
90-Day Vol
65.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.19 – C$1.68 |
| 60 trading days | C$1.33 | C$1.04 – C$1.70 |
| 90 trading days | C$1.25 | C$0.93 – C$1.70 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should note Helix BioPharma's recent financial disclosures and strategic initiatives as they navigate the company's ongoing developments and potential for future growth.
Helix BioPharma Corp. Closes at C$1.50, Up 4.17% This Week
With a market cap of approximately C$114.57 million and a recent surge in trading volume, Helix BioPharma may be attracting renewed interest from investors.
Bull case
Analysts are optimistic about Helix BioPharma, with an average target price of C$2.50. This suggests there could be significant upside as the company continues to align its strategies with market expectations.
Bear case
On the other hand, the company has faced challenges, including a year-to-date decline of 37.50% and some negative financial metrics. These factors may discourage certain investors from entering or maintaining their positions.
Weekly Price Action
Helix BioPharma Corp. has closed the week at C$1.50, reflecting a modest increase of 4.17% over the past week. Despite this uptick, the stock has seen a year-to-date decline of 37.50%, which may raise concerns among investors regarding the company's overall performance.
Company News and Recent Headlines
Advertisement
Recent headlines surrounding Helix BioPharma include the announcement of financial results and interim statements for various periods, as well as the granting and cancellation of stock options. Notably, the company reported its financial results for the three- and nine-month periods ending April 30, 2026, and has been actively pursuing a private placement to bolster its capital structure. These initiatives reflect the company's ongoing efforts to navigate a challenging market environment.
Technical Picture
From a technical standpoint, Helix BioPharma's last close of C$1.50 is slightly above the 50-day moving average of C$1.49, indicating a short-term bullish trend. However, the stock remains significantly below its 200-day moving average of C$1.92, suggesting long-term challenges. The stock's 52-week range of C$0.98 to C$5.40 indicates that it is currently trading at approximately 12% of its highest point in the past year. With a beta of -0.35, the stock exhibits lower volatility compared to the broader market.
Insider Activity
Helix BioPharma has granted 1,297,000 incentive stock options to its directors, officers, employees, and consultants while canceling 2,200,000 previously granted options. This move could indicate a strategic shift in how the company is incentivizing its key personnel, aligning their interests with shareholders.
Price Action Summary
As of the last close, Helix BioPharma Corp. is trading at C$1.50, reflecting a 1D change of 0.00%. While the weekly performance shows a positive trend, investors should remain cautious and consider the overall financial health and strategic direction of the company.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
